Latest Developments in Lek-Novartis Story Looked at by Vecer
Maribor, 11 October - It is strange that Metod Dragonja is still chair of the pharmaceuticals company Lek, since it is him and his colleagues who believe that it would benefit Lek were it bought by the Swiss Novartis. His promoting of this opinion in the media even augmented the expenses of the company and consequently decreased its profit, the daily Vecer observes.
The rest of this news item is available to subscribers.
The news item consists of 928 characters (without spaces) or 191 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.